[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100474528":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":20,"centralContacts":24,"locations":34,"responsibleParty":50,"collaborators":19,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":19,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":19,"enrollmentInfo":61,"targetDuration":19,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":19,"overallStatus":71,"whyStopped":19,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Duke University","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Aim 3B","This aim will evaluate the feasibility and acceptability of the adapted health care delivery intervention to improve anti-hypertensive medication adherence and blood pressure control in persons living with HIV at 24 weeks.",[12],"Behavioral: Hypertension control through education and monitoring",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"BEHAVIORAL","Hypertension control through education and monitoring","Enrollment of 60 PLWH ≥18 years old receiving care at the Duke ID clinic who have achieved HIV viral suppression who take antihypertensive medication and have uncontrolled blood pressure. Subjects will have be given educational materials, blood pressure monitors to use and report findings, follow up with study coordinator and communication with subject's HIV provider in order to maximize blood pressure control..",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Charles Muiruri, PhD","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Stuart T Carr, BA","CONTACT","919 668-4849","stuart.carr@duke.edu",{"name":31,"role":27,"phone":32,"phoneExt":19,"email":33},"Mersedes Brown, MPH","919 668-7364","mersedes.brown@duke.edu",[35],{"facility":5,"status":19,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Durham","North Carolina","27710","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-78.89862,35.99403,{"lat":45,"lon":44},[48],{"name":31,"role":27,"phone":49,"phoneExt":19,"email":33},"919-668-7364",{"type":51,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100474528","addressing-barriers-to-anti-hypertensive-medication-adherence-among-plwh-who-have-achieved-viral-suppression-100474528",false,"NCT05459077","Addressing Barriers to Anti-hypertensive Medication Adherence Among PLWH Who Have Achieved Viral Suppression","Addressing Barriers to Anti-hypertensive Medication Adherence Among Persons Living With HIV Who Have Achieved Viral Suppression","Inclusion Criteria:\n\nAims 1A and 1B\n\n* Age ≥18 years\n* Confirmed HIV+ diagnosis\n* Undetectable HIV viral load: defined as the most recent HIV viral load \\\u003C200 copies\u002FmL checked within the past year (assessed via chart abstraction)\n* Hypertension diagnosis in medical records\n* Taking an antihypertensive medication\n* Receiving care at the Duke HIV clinic\n\nAim 2\n\n* HIV providers including infectious disease physicians, internists or advance practice practitioners who have a patient pool of PLWH under their care in the last 6 months.\n\nAim 3A\n\n* Stakeholders composed of willing participants recruited from the Duke ID clinic and may include, HIV providers, clinic directors, nurses, pharmacists, social workers, people living with HIV who have hypertension and take antihypertensive medications, and representatives of the community advisory boards, and any other key stakeholders.\n\nAim 3 B\n\n* Age ≥18 years\n* Confirmed HIV+ diagnosis\n* Receiving care at the Duke ID clinic\n* Achievement of HIV suppression defined as having HIV-1 RNA \\\u003C200 copies\u002Fml\n* Take antihypertensive medications\n* Uncontrolled BP over a 12 months period defined by participants with systolic BP\\>130mmHg on ≥ 2 occasions in the past 12 months as indicated in the individual patient's electronic medical records\n\nExclusion Criteria:\n\nAims 1A, 1B and 3B\n\n* Severely hearing or speech impaired, or other disability that would limit participation in the intervention components\n* In a nursing home and\u002For receiving in-patient psychiatric care\n* Terminal illness with life expectancy \\\u003C 4 months\n* No reliable access to a telephone\n* Pregnant, breast-feeding, or planning a pregnancy during the study period\n* Planning to move out of the area in the next 6 months\n* Non-English speaking.","ALL","18 Years",{"count":62,"type":63},60,"ESTIMATED","INTERVENTIONAL",[66],"NA","Among those with hypertension, persons living with HIV (PWH) have a 50% higher risk of incident myocardial infarction compared to the general population, and they often fail to meet evidence-based treatment goals for hypertension. An important contributing factor for insufficient blood pressure control is non-adherence to antihypertensive medications. Research on medication adherence for PWH has largely focused on antiretroviral therapy adherence with limited focus on adherence to other non-AIDS condition medications.\n\nWith a large proportion of PWH in the U.S. achieving viral suppression, providers may now have an opportunity to focus on the management of non-AIDS conditions like hypertension. However, because PWH who have achieved suppression have reduced clinic encounters (once or twice a year) there is potential loss of opportunity to effectively monitor and intensify hypertension treatment as needed an important opportunity to focus on preventing cardiovascular disease. CVD and other non-AIDS comorbidities.\n\nThe study's overarching goal is to improve the hypertension outcomes for PWH on suppressive ART to reduce cardiovascular disease risk. In this study, we will identify and evaluate healthcare and patient-level factors that must be addressed in an intervention to increase hypertension medication adherence for PWH who have achieved viral suppression. We will use these factors to tailor an intervention and assess the feasibility and acceptability at the Duke ID clinic.",[69,70],"Hypertension","HIV-1-infection","NOT_YET_RECRUITING","2026-03-25",{"date":74,"type":75},"2026-03-30","ACTUAL",{"date":77,"type":63},"2026-04-20",{"date":79,"type":63},"2026-09-30",{"name":5,"class":6},1]